More recently, we identified SOX11 to be specifically overexpressed in the vast majority of malignant gliomas (Weigle et al, 2005) and demonstrated the generation of SOX11 peptide-reactive CTLs that were capable of lysing HLA-matched glioma cell lines (Schmitz et al, 2007). This evidence concerns the gene SOX11 and central nervous system cancer.